| 27.82 -0.18 (-0.64%) | 10-08 16:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.18 | 1-year : | 34.11 |
| Resists | First : | 28.41 | Second : | 29.2 |
| Pivot price | 28.07  |
|||
| Supports | First : | 27.12 | Second : | 22.56 |
| MAs | MA(5) : | 27.7 |
MA(20) : | 27.96 |
| MA(100) : | 26.12 |
MA(250) : | 25.43 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 28.7 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 29.2 | Low : | 22.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PFE ] has closed above bottom band by 34.9%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.03 - 28.19 | 28.19 - 28.34 |
| Low: | 27.1 - 27.28 | 27.28 - 27.44 |
| Close: | 27.57 - 27.85 | 27.85 - 28.1 |
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Thu, 08 Oct 2026
PFIZER INC (PFE-USD.SW) Q2 FY2026 earnings call transcript - Yahoo Finance
Thu, 08 Oct 2026
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - TradingView
Thu, 08 Oct 2026
Pfizer Inc. (PFE) Options Chain - Yahoo! Finance Canada
Thu, 08 Oct 2026
Pfizer to close penicillin unit, cut around 330 jobs in Italy (PFE:NYSE) - Seeking Alpha
Wed, 07 Oct 2026
Lobbying Update: $4,430,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Wed, 07 Oct 2026
Pfizer Inc. Stock Grades | PFE - Barron's
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 5,700 (M) |
| Shares Float | 5,690 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 69.1 (%) |
| Shares Short | 155,200 (K) |
| Shares Short P.Month | 149,270 (K) |
| EPS | 0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.94 |
| Profit Margin | 6.8 % |
| Operating Margin | 27.8 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 5 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 8.34 |
| Sales Per Share | 11.17 |
| EBITDA (p.s.) | 4.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13,400 (M) |
| Levered Free Cash Flow | 12,490 (M) |
| PE Ratio | 36.6 |
| PEG Ratio | 12.9 |
| Price to Book value | 1.86 |
| Price to Sales | 2.48 |
| Price to Cash Flow | 11.83 |
| Dividend | 0.43 |
| Forward Dividend | 0 |
| Dividend Yield | 1.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|